ANDA 210531, held by Mylan. Dimethyl Fumarate.
As of Nov 16, 2026, ANDA 210531 (Dimethyl Fumarate), held by Mylan, was first approved by FDA on Aug 17, 2020, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 17, 2020 | Original application | Approved |
| Dimethyl Fumarate120MG · capsule, delayed release;oral | Dimethyl Fumarate | Discontinued |
| Dimethyl Fumarate240MG · capsule, delayed release;oral | Dimethyl Fumarate | Discontinued |
| Apr 30, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 30, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 30, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 30, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 30, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 17, 2021 | Supplement 1Manufacturing | Approved | None posted |
| Aug 17, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters